To further assess the methylation of EBF3 and TBC1D16, we also investigated the same CpG sites in additional WGBS of cancer samples from TCGA, consisting of primary tumour samples for urothelial bladder carcinoma, breast invasive carcinoma, colon adenocarcinoma, glioblastoma multiforme, lung adenocarcinoma, lung squamous cell carcinoma, rectum adenocarcinoma, stomach adenocarcinoma and uterine corpus endometrial carcinoma (Fig. 5). This evidence concerns the gene TBC1D16 and bladder transitional cell carcinoma.